Press Releases

Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division

Company intend to move veterinary assets to United States; plans new FDA study

Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea® (Paclical®)

Results from a dose-finding study with weekly administration of Apealea (alternatively branded Paclical in some international regions) in patients with metastatic breast cancer are now available.

Oasmia Pharmaceutical AB’s Warrant Programs Fully Subscribed

Uppsala, Sweden, December 7, 2016 --- Oasmia Pharmaceutical (publ.) (”Oasmia” or ”The Company”) announces hereby that the previously announced warrant programs for the Oasmia management and Bo...

Interim report for the period May – October 2016

Expanded product portfolio and secured financing

Communiqué from Extraordinary General Meeting 2016

Oasmia Pharmaceutical AB (publ.), with VAT no SE556332-667601, held on Monday, November 21, 2016, an Extraordinary General Meeting where the following main resolutions were made. For more detailed inf...

Nexttobe Extends Loan to Oasmia Pharmaceutical

Uppsala, Sweden, November 2, 2016 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has extend...

Oasmia Pharmaceutical Announces Change in Ownership

Uppsala, Sweden, November 1, 2016 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology announced today that Nexttobe AB has divest...

Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ)

As of October 31, 2016, the total number of shares and voting rights in Oasmia Pharmaceutical AB (publ) (”Oasmia”) is 119,039,310. Oasmia has, in accordance with previously disclosed informatio...

Oasmia convenes an extraordinary general meeting on the 21 November, 2016

Uppsala, Sweden, October 26, 2016 -- Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company convenes to an extraordinary general meeting.

Oasmia issues new shares for acquiring an asset corresponding to SEK 25 million

Uppsala, Sweden, October 24, 2016 -- Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has made an offset issue of 3,080,000 new shares in order to ...